Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$13.50 -0.3%	$12.79	$8.04 ▼ $25.88	$367.21M	2.27	416,565 shs	278,097 shs
BNTC Benitec Biopharma	$11.04 -6.0%	$14.01	$7.05 ▼ $17.15	$308.18M	0.37	58,543 shs	98,440 shs
GOSS Gossamer Bio	$1.70 -0.6%	$1.27	$0.66 ▼ $1.90	$388.69M	1.86	1.47 million shs	3.18 million shs
JUSHF Jushi	$0.38 -6.3%	$0.33	$0.22 ▼ $0.69	$80.62M	-1.06	127,686 shs	71,818 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-0.30%	-2.03%	+9.31%	+28.21%	-44.40%
BNTC Benitec Biopharma	-5.96%	-13.62%	-26.10%	-19.71%	+13.81%
GOSS Gossamer Bio	-0.58%	+25.00%	+31.78%	+102.38%	+55.96%
JUSHF Jushi	-6.34%	-15.92%	+31.60%	+20.00%	-33.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	1.9693 of 5 stars	3.6	0.0	0.0	2.0	2.5	0.6
BNTC Benitec Biopharma	1.6844 of 5 stars	3.6	1.0	0.0	2.8	0.8	0.0
GOSS Gossamer Bio	3.7723 of 5 stars	3.5	1.0	4.7	2.4	1.7	0.0
JUSHF Jushi	1.7126 of 5 stars	0.0	5.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$54.00	300.00% Upside
BNTC Benitec Biopharma	3.20	Buy	$23.83	115.88% Upside
GOSS Gossamer Bio	3.00	Buy	$8.25	385.29% Upside
JUSHF Jushi	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest JUSHF, ARCT, BNTC, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$152.31M	2.40	N/A	N/A	$8.90 per share	1.52
BNTC Benitec Biopharma	$80K	3,622.50	N/A	N/A	$4.68 per share	2.36
GOSS Gossamer Bio	$114.70M	3.37	N/A	N/A	$0.13 per share	13.08
JUSHF Jushi	$257.52M	0.29	N/A	N/A	($0.26) per share	-1.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
JUSHF Jushi	-$48.78M	-$0.24	N/A	N/A	N/A	-18.54%	N/A	-10.71%	8/6/2025 (Estimated)

Latest JUSHF, ARCT, BNTC, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	N/A	N/A	N/A	$4.12 million	N/A
8/6/2025	N/A	JUSHF Jushi	-$0.06	N/A	N/A	N/A	$64.67 million	N/A
8/4/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	N/A	N/A	N/A	$17.64 million	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/8/2025	Q1 2025	JUSHF Jushi	-$0.06	-$0.09	-$0.03	-$0.09	$66.23 million	$63.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
JUSHF Jushi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	0.06	5.64	5.64
BNTC Benitec Biopharma	0.01	14.80	14.80
GOSS Gossamer Bio	6.70	5.71	5.71
JUSHF Jushi	N/A	1.13	0.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
BNTC Benitec Biopharma	52.19%
GOSS Gossamer Bio	81.23%
JUSHF Jushi	21.68%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
BNTC Benitec Biopharma	1.30%
GOSS Gossamer Bio	6.70%
JUSHF Jushi	22.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
JUSHF Jushi	1,234	196.63 million	152.43 million	Not Optionable

JUSHF, ARCT, BNTC, and GOSS Headlines

Recent News About These Companies

Polypropylene Chopped Strands Market Report 2025-2034 | Asia-Pacific Leads with Strong Manufacturing Base with Owens Corning, China Jushi, and Saint Gobain Leading

July 16 at 5:00 AM | globenewswire.com

Jushi (OTCMKTS:JUSHF) Shares Down 13.4% - Should You Sell?

July 16 at 3:13 AM | marketbeat.com

JUSHF - Jushi Holdings Inc Chart | Morningstar

June 26, 2025 | morningstar.comM

Jushi (OTCMKTS:JUSHF) Stock Price Down 2.2% - Here's What Happened

June 24, 2025 | marketbeat.com

Jushi and Real Housewives Star Stacey Rusch Celebrate Successful Launch of Lifestyle Cannabis ...

June 23, 2025 | bakersfield.comB

Jushi and Real Housewives Star Stacey Rusch Celebrate Successful Launch of Lifestyle Cannabis Brand ‘Shayo’

June 23, 2025 | financialpost.comF

3 Top Marijuana Stocks If You Plan To Make A Profit In The Cannabis Sector

June 16, 2025 | marijuanastocks.comM

Jushi Holdings Inc. Announces Voting Results of Annual Shareholders' Meeting

June 3, 2025 | globenewswire.com

Jushi Holdings Inc. Announces Voting Results of Annual Shareholders’ Meeting

June 3, 2025 | financialpost.comF

3 Marijuana Stocks That Make The Cannabis Industry Better

June 2, 2025 | marijuanastocks.comM

Jushi Holdings Inc. Earnings Call: Mixed Sentiments and Strategic Expansion

May 9, 2025 | tipranks.com

Jushi Holdings Inc. (JUSHF) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

Jushi Holdings Inc. (JUSHF) Reports Q1 Loss, Lags Revenue Estimates

May 8, 2025 | zacks.com

Jushi Holdings Reports Q1 2025 Financial Results and Expansion Plans

May 8, 2025 | tipranks.com

Jushi Holdings Inc. Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Jushi Holdings Inc. Updates Call Time to 4:00 p.m. Eastern Time to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025 | financialpost.comF

Jushi Holdings Inc. Updates Call Time to 4:00 p.m. Eastern Time to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025 | globenewswire.com

Economic impact of U.S. cannabis industry set to double over next six years

April 25, 2025 | msn.com

Jushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025 | JUSHF Stock News

April 23, 2025 | gurufocus.com

Jushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025 | JUSHF Stock News

April 23, 2025 | gurufocus.com

Jushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025

April 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUSHF, ARCT, BNTC, and GOSS Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$13.50 -0.04 (-0.30%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$13.65 +0.15 (+1.14%)

As of 07/18/2025 07:56 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Benitec Biopharma NASDAQ:BNTC

$11.04 -0.70 (-5.96%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$11.06 +0.02 (+0.14%)

As of 07/18/2025 07:22 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Gossamer Bio NASDAQ:GOSS

$1.70 -0.01 (-0.58%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.68 -0.02 (-1.47%)

As of 07/18/2025 06:33 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Jushi OTCMKTS:JUSHF

$0.38 -0.03 (-6.34%)

As of 07/18/2025 03:59 PM Eastern

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time